What's in Sang Gyune Kim's pipeline?

Sang Gyune Kim has 1 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Sang Gyune Kim's portfolio?

Top competitors by shared drug class: Hospices Civils de Lyon, Iran Hepatitis Network, Qing XIe.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sang-gyune-kim.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Sang Gyune Kim — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sang Gyune Kim pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Hospices Civils de Lyon · 1 shared drug class
Iran Hepatitis Network · 1 shared drug class
Qing XIe · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sang Gyune Kim:

Cite this brief

Drug Landscape (2026). Sang Gyune Kim — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sang-gyune-kim. Accessed 2026-05-16.